Ashland Inc.
NYSE•ASH
執行長: Mr. Guillermo Novo
板塊: Basic Materials
行業: Chemicals - Specialty
上市日期: 1980-03-17
Ashland Inc. provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; and nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives. Its Personal Care segment provides a range of natural, nature-derived, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. Its Intermediates segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. and changed its name to Ashland Inc. in August 2022. Ashland Inc. was founded in 1924 and is headquartered in Wilmington, Delaware.
聯絡資訊
市值
$2.59B
本益比 (TTM)
-3.8
29.7
股息率
2.9%
52周最高
$65.65
52周最低
$46.30
52周範圍
排名42Top 47.5%
3.9
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 3.9 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q1 2026 數據
營業收入
$386.00M-4.69%
近4季度走勢
每股收益
-$0.26-92.57%
近4季度走勢
自由現金流
$111.00M-276.19%
近4季度走勢
2026 Q1 財報亮點
核心亮點
Net Loss Significantly Narrows Net loss reduced to $(12)M for the quarter, a $153M improvement versus prior year period results.
Operating Cash Flow Strong Cash provided by operating activities from continuing operations reached $125M, up from $(30)M outflow last year.
Adjusted EBITDA Slight Dip Adjusted EBITDA was $58M, slightly down $3M from $61M, driven by portfolio optimization impacts.
Divestiture Impact on Sales Total sales were $386M, down $19M, reflecting an $11M volume drop and $10M impact from Avoca business sale.
關注風險
Credit Rating Downgrade Risk Moody's Investor Services downgraded corporate credit rating to Ba2 during the quarter, potentially affecting future borrowing costs.
Lower Volume Pressures Sales Total sales decreased $19M, driven by lower volume and unfavorable pricing, partially offset by favorable foreign currency exchange.
Trade Policy Geopolitical Uncertainty Continuing regulatory activity regarding tariffs and global trade disputes creates macroeconomic and geopolitical uncertainty risks.
Asbestos Litigation Reserves Large Total reserves for Ashland's asbestos claims stood at $246M at period end, subject to future estimation changes.
未來展望
FY2026 Adjusted EBITDA Narrowed Full year fiscal 2026 Adjusted EBITDA guidance narrowed to $400M to $420M range, reflecting temporary impacts.
Optimization Program Cost Savings Manufacturing optimization program on track, expecting $30M cost savings under the $90M program for fiscal 2026.
Core Markets Remain Resilient Personal Care and Life Sciences core end markets expected to remain resilient, supported by stable fundamentals and innovation traction.
Share Repurchase Availability High $520 million remained available for repurchase under the $1B evergreen stock repurchase program as of December 31, 2025.
同行對比
營業收入 (TTM)
$8.05B
$5.81B
$3.59B
毛利率 (最新季度)
55.6%
34.4%
32.3%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| MEOH | $4.62B | 57.9 | 3.2% | 48.2% |
| SKE | $4.02B | -29.8 | -148.5% | 8.2% |
| AVNT | $3.46B | 42.3 | 3.5% | 31.9% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
-6.9%
增長承壓
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
100%
現金流表現優異
深度研究
下次財報:2026年4月28日
每股收益:-
|營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料